Prospective Comparison of Cirrus Versus Stratus Ocular Coherence Tomography for Different Retinal Pathology.

This study has been completed.

Sponsor:

Collaborator:

Research to Prevent Blindness

Information provided by:

University of Chicago

ClinicalTrials.gov Identifier:

NCT00731458

First received: August 6, 2008

Last updated: August 8, 2008

Last verified: August 2008

History of Changes

Purpose

Ocular Coherence Tomography (OCT) is a non-invasive ophthalmologic test that uses reflected, unheated, non-concentrated visible light in order to scan and provide a 2-dimensional topographic analysis of the retina and optic nerve. It has wide diagnostic utility especially in patients with clinically significant macular edema, glaucoma, and other retinal eye diseases. At the University of Chicago, we have utilized the Stratus brand OCT (Carl Zeiss Inc) for the past 5 years. Recently we have acquired a beta version of the company's new model, the Cirrus HD-OCT (Carl Zeiss Inc.) which features improved resolution, shorter scanning time and a more user-friendly interface. The purpose of this study is to compare findings between the two models in patients with different common and uncommon eye diseases, including diabetic macular edema, glaucoma and age-related macular degeneration. We hypothesis that the Cirrus OCT is able to accurately quantify eye pathology compared to Stratus OCT.

Condition	Intervention
Retinal Pathology	Device: Optical coherance tomography ( Cirrus; Stratus)

Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Health Services Research
Official Title:	Prospective Comparison of Cirrus and Stratus Optical Coherence Tomography for Quantifying Retinal Thickness

Further study details as provided by University of Chicago:

Enrollment:	60
Study Start Date:	May 2007
Study Completion Date:	November 2007
Primary Completion Date:	November 2007 (Final data collection date for primary outcome measure)

Intervention Details:

Non-contact retinal thickness analyzer

Other Name: OCT; Cirrus; Stratus

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Any eye pathology that may cause macular edema.

Exclusion Criteria:

Vitreous media opacities including dense cataracts, vitreous hemorrhage, and corneal opacities

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00731458

Sponsors and Collaborators

University of Chicago

Research to Prevent Blindness

Investigators

Principal Investigator:

Seenu Hariprasad, M.D.

University of Chicago

More Information

Publications:

Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Evaluation of Time Domain and Spectral Domain Optical Coherence Tomography in the Measurement of Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2008 May 30; [Epub ahead of print]

Gupta V, Gupta P, Singh R, Dogra MR, Gupta A. Spectral-domain Cirrus high-definition optical coherence tomography is better than time-domain Stratus optical coherence tomography for evaluation of macular pathologic features in uveitis. Am J Ophthalmol. 2008 Jun;145(6):1018-1022. Epub 2008 Mar 17.

Responsible Party:	Seenu M Hariprasad, University of Chicago
ClinicalTrials.gov Identifier:	NCT00731458 History of Changes
Other Study ID Numbers:	15606B
Study First Received:	August 6, 2008
Last Updated:	August 8, 2008
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Chicago:

OCT;
Cirrus;
Stratus;
macular thickness

ClinicalTrials.gov processed this record on May 21, 2013

To Top